Immunome to Present at Upcoming Investor Conferences
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company, announced that its management team will present at two upcoming investor conferences: the 9th Annual Evercore Healthcare Conference on December 1, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. Live audio webcasts and replays of these presentations will be available via the company’s investor relations website. Immunome is focused on developing first-in-class and best-in-class cancer therapies, including a portfolio of antibody-drug conjugates (ADCs) and a radioligand therapy.
Four Wellington entities report a stake above 5% in Immunome (IMNM).
Four Wellington entities, including Wellington Management Group LLP and Wellington Management Company LLP, have reported beneficial ownership of 6,041,333 shares of Immunome Inc. (IMNM) common stock, representing a 5.32% stake in the company. These shares are held of record by clients of Wellington investment advisers, who retain the rights to dividends and sale proceeds. No single client is known to have rights over more than 5% of the class.
Why Immunome (IMNM) Shares Climbed After Its Latest Update
Immunome (IMNM) shares saw an 8.48% rise over one month and 6.51% over seven days, despite wider third-quarter losses and new shelf registrations. The company's stock is currently trading at US$19.07, significantly below the analyst consensus fair value of $36.31, largely due to its late-stage oncology pipeline, particularly varegacestat. An FDA acceptance for varegacestat with a PDUFA date of April 28, 2027, suggests a potential shift towards product sales, offering a path to meaningful revenue despite the inherent risks in FDA review and market adoption.
Liquidity Mapping Around (IMNM) Price Events
This report provides a liquidity mapping analysis for Immunome Inc. (NASDAQ: IMNM), highlighting conflicting sentiment across different time horizons. It outlines three AI-generated trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT), complete with entry, target, and stop levels. The analysis also identifies key support and resistance levels across near-term, mid-term, and long-term perspectives.
Does Regulatory Progress Change The Bull Case For Immunome Stock (IMNM)?
Immunome reported Q3 2026 results with a net loss of US$85.78 million but advanced its lead therapeutic, varegacestat, into EU regulatory review, alongside progress in its oncology pipeline. The company broadened its financing options through shelf registrations, providing flexibility to raise funds for its pipeline. While the near-term focuses on regulatory execution and commercialization for varegacestat, Immunome's long-term narrative projects significant revenue and earnings by 2029, albeit with substantial current losses and reliance on external capital.
Piper Sandler lowers Immunome stock price target to $30 on higher costs
Piper Sandler has reduced its price target for Immunome Inc. (NASDAQ:IMNM) to $30 from $33, while maintaining an Overweight rating, due to higher operating expenses. The new target still suggests approximately 55% upside potential from its current trading price of $19.36, despite analysts not expecting the company to be profitable this year. Immunome also provided pipeline updates, including presenting ROR1-ADC IM-1021 data at ASH and initiating a Phase 1 study for IM-1340 by year-end 2026.
IMNM: Varegacestat nears a 2027 FDA decision as ADC development advances on IM-1021 data
Immunome, Inc. (IMNM) is progressing Varegacestat towards an FDA decision by the end of April 2027, with global launch preparations underway. The company is also prioritizing antibody-drug conjugate (ADC) development, including novel-target programs and anticipated IM-1021 ROR1 data, which previously showed a 53% response rate. This information is based on Immunome's 3rd Annual Guggenheim Healthcare Innovation Conference audio transcript from November 10, 2026.
Piper Sandler lowers Immunome stock price target to $30 on higher costs
Piper Sandler has reduced its price target for Immunome Inc. (NASDAQ:IMNM) to $30 from $33, while maintaining an Overweight rating, due to higher operating expenses. Despite the reduction, the new target still suggests a 55% upside potential from the current trading price of $19.36. The company recently reported Q3 2026 results and provided pipeline updates, including data presentations, FDA clearance for a new drug application, and plans for a Phase 1 study, alongside building its commercial team for varegacestat.
After $65.9M in prior share sales, Immunome (IMNM) may sell more stock.
Immunome Inc. (IMNM) has filed an automatic shelf registration statement to offer up to $134.1 million in common stock through TD Cowen. This follows a prior sales agreement where the company sold 6,655,587 shares for $65.9 million. Proceeds are intended for general corporate purposes, including R&D, clinical expenses, and potential acquisitions.
Immunome, Inc. (IMNM) Misses Q3 EPS by 16c
Immunome, Inc. (IMNM) reported a Q3 EPS of ($0.76), which was $0.16 worse than the analyst estimate of ($0.60). This information is critical for investors and traders following the company's financial performance.
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
Immunome, Inc. announced the presentation of initial first-in-human clinical data for IM-1021, a ROR1-targeted antibody-drug conjugate, in advanced B-cell lymphomas at the 68th ASH Annual Meeting. The data showed an objective response rate of 53% in heavily pretreated patients with B-cell non-Hodgkin lymphoma, including complete responses, and 64% in diffuse large B-cell lymphoma patients. These early results support ongoing dose optimization efforts for IM-1021.
Immunome (IMNM) Dropped, So What Is Behind The Latest Attention?
Immunome (IMNM) saw a recent share price drop of 3.89% despite positive clinical and regulatory news, including the European Medicines Agency validating its Marketing Authorization Application for varegacestat and new Phase 3 data. The company is considered 46% undervalued by some analysts, with a fair value of $36.31 against its current price of $19.52, largely dependent on the success of its varegacestat pipeline. However, its P/B ratio of 4.4x is higher than industry averages, suggesting a richer valuation based on balance sheet pricing.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
The third-quarter 2026 earnings season is underway for the Medical sector, with many companies, especially in biotech, poised to surpass earnings estimates. This article highlights four biotech companies—TG Therapeutics (TGTX), Immunome (IMNM), REGENXBIO (RGNX), and Promis Neurosciences (PMN)—that are expected to deliver earnings beats. These companies exhibit strong fundamentals, promising pipeline developments, and positive Earnings ESP values combined with favorable Zacks Ranks.
How EMA Filing Validation At Immunome (IMNM) Has Changed Its Investment Story
Immunome (IMNM) announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application for varegacestat, an oral treatment for desmoid tumors. This validation, supported by positive Phase 3 trial data showing reduced symptom burden and improved physical function, tightens the focus on regulatory execution in both Europe and the US. The key near-term catalyst remains the FDA PDUFA date on April 28, 2027, with successful approval crucial for the company's financial projections and broader oncology ambitions.
How EMA Filing Validation At Immunome (IMNM) Has Changed Its Investment Story
Immunome announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application for varegacestat, a drug for desmoid tumors, supported by positive Phase 3 trial data and detailed patient-reported outcomes. This validation shifts the investment focus to execution and regulatory outcomes, particularly with the FDA's PDUFA date in April 2027. Analysts project significant revenue and earnings growth for Immunome by 2029 if varegacestat successfully transitions to a commercial franchise.
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Immunome, Inc. announced its management will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST. The clinical-stage targeted oncology company will make the live audio webcast of the presentation available from the Investor Relations section of its website. Immunome is focused on developing first-in-class and best-in-class targeted cancer therapies, including antibody-drug conjugates (ADCs), and has several clinical-stage and IND-cleared candidates in its pipeline.
Weekly Recap: 84% lower progression or death risk and week-48 symptom and function gains
Immunome, Inc. (NASDAQ:IMNM) reported significant Phase 3 RINGSIDE results for varegacestat, demonstrating an 84% reduction in progression or death risk and improved patient symptoms and physical function compared to placebo. Wedbush reiterated an Outperform rating with a $35 price target, while ESMO posters provided additional supporting data on MRI changes, safety, and dose-response.
Immunome, Inc. (IMNM)
This article provides a financial overview of Immunome, Inc. (IMNM), including its current stock price, market capitalization, and key performance indicators. It highlights significant institutional holdings by firms like Renaissance Technologies and Citadel Advisors, detailing their ownership percentages and recent activity. The page also presents price performance data and an estimated next earnings date.
Immunome’s Varegacestat Moves into European Regulatory Review Following Positive Phase III Results
Immunome, Inc. announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an investigational oral therapy for adults with desmoid tumors. This validation initiates the EMA's review process, supported by positive Phase 3 RINGSIDE trial results showing an 84% reduction in disease progression or death risk. If approved, varegacestat could offer a new oral treatment option for patients in the European Union, following its New Drug Application acceptance by the U.S. FDA with a target action date of April 28, 2027.
Understanding the Setup: (IMNM) and Scalable Risk
This article analyzes Immunome Inc. (NASDAQ: IMNM), highlighting strong near-term sentiment and a long-term positive bias despite elevated downside risk. It provides three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes optimizing position sizing and minimizing drawdown risk using sophisticated risk management parameters.
EMA validates Immunome application for desmoid tumor treatment
The European Medicines Agency (EMA) has validated Immunome Inc.'s Marketing Authorization Application for varegacestat, an oral treatment for desmoid tumors. This validation initiates the EMA's review process, supported by positive Phase 3 RINGSIDE trial results showing an 84% reduction in disease progression or death risk and significant improvement in pain and tumor volume. The U.S. FDA also accepted Immunome’s New Drug Application for varegacestat in July, with an action date set for April 28, 2027.
Vanguard reports a stake above 5% in Immunome (IMNM), including funds and client accounts.
Vanguard Capital Management has reported a beneficial ownership stake of 5.04% in Immunome Inc. (IMNM), totaling 5,725,578 common shares. This ownership includes securities held by various Vanguard funds and client accounts, with Vanguard Capital Management LLC and its affiliates exercising dispositive and/or voting power. The filing, a SCHEDULE 13G, indicates that no other person's interest in these reported securities exceeded 5%.
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome, Inc. announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for varegacestat, an investigational oral therapy for adults with desmoid tumors. This validation initiates the EMA's review process, supported by positive Phase 3 RINGSIDE trial data demonstrating significant improvements in progression-free survival and objective response rates. If approved, varegacestat could offer a new oral treatment option for desmoid tumor patients in the EU, following the FDA's acceptance of the New Drug Application in the U.S.
Immunome gets EMA validation for varegacestat in desmoid tumors
Immunome, Inc. announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for varegacestat, an investigational oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. This validation initiates the EMA's review process, following the U.S. FDA's acceptance of a New Drug Application for the same drug. The application is supported by positive Phase 3 RINGSIDE trial data, which demonstrated an 84% reduction in disease progression or death risk and significant improvements in objective response rate and pain intensity.
Is Immunome (IMNM) Undervalued After New Varegacestat Data And FDA Review Progress?
Immunome (IMNM) is under scrutiny after presenting new clinical data for varegacestat and advancing regulatory reviews. Despite short-term share price declines, the company shows long-term momentum and is considered 48% undervalued by a popular narrative, trading at $18.76 against a fair value of $36.31. However, some market ratios suggest it might be expensive on book value, indicating mixed signals for investors.
Is Immunome (IMNM) Undervalued After New Varegacestat Data And FDA Review Progress?
Immunome (IMNM) is gaining attention after presenting new clinical data for varegacestat in desmoid tumors and advancing regulatory reviews in the US and Europe. Despite recent short-term share price declines, the company shows strong long-term shareholder returns, and its stock is considered 48% undervalued by analysts, suggesting a potential valuation gap. Immunome is expanding its oncology platform with multiple assets in Phase 1 trials, aiming for diversified revenue streams and improved margins.
H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright has reaffirmed its Buy rating on Immunome (IMNM.US) and maintained its target price of $40. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Immunome stock price target maintained at $40 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Immunome Inc. (NASDAQ:IMNM), citing positive clinical data presentations at ESMO. The firm highlighted varegacestat's positive impact on the quality of life for desmoid tumor patients, noting significant improvements in pain and symptoms. Other analyst firms like William Blair and Stifel have also initiated or maintained coverage, with varying ratings and price targets, following recent corporate developments including a licensing agreement with Bristol.
Immunome stock price target maintained at $40 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Immunome Inc. (NASDAQ:IMNM), citing positive clinical data for varegacestat in desmoid tumor patients. The analysis indicates the stock is currently undervalued at $17.89 compared to a Fair Value of $20.26, despite high volatility. These developments follow Immunome's recent licensing agreement with Bristol and new analyst coverage from William Blair (Outperform) and Stifel (Hold).
Will New Desmoid Tumor Data Change Immunome (IMNM) Stock Narrative
Immunome recently released new RINGSIDE trial data at the 2026 ESMO Congress, showing that varegacestat improved symptoms and physical function in desmoid tumor patients, in addition to previously reported objective response and progression-free survival outcomes. With an accepted FDA NDA for varegacestat, this new data could help shift Immunome's narrative from a pure R&D company towards its first commercial product, potentially funding a broader oncology pipeline. The key near-term catalyst is the FDA decision on the desmoid tumor NDA, with a PDUFA date of April 28, 2027, which could transform the company from a zero-revenue biotech with heavy losses to a revenue-generating entity.
Immunome stock price target maintained at $40 by H.C. Wainwright
H.C. Wainwright reiterated a Buy rating and a $40 price target for Immunome Inc. (NASDAQ:IMNM) after the company presented clinical data at ESMO, highlighting varegacestat's positive impact on the quality of life for desmoid tumor patients. Despite high stock volatility, Immunome maintains a strong balance sheet with more cash than debt. Other recent analyst actions include William Blair initiating coverage with an Outperform rating and Stifel initiating and maintaining a Hold rating.
Immunome stock price target maintained at $40 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Immunome Inc. (NASDAQ:IMNM) following positive clinical data for varegacestat in desmoid tumor patients. The data showed improvements in patient-reported quality of life metrics, including reduced pain and symptoms. Other analyst firms, William Blair and Stifel, have also initiated coverage, with William Blair setting an Outperform rating and Stifel maintaining a Hold rating.
Immunome stock price target maintained at $40 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Immunome Inc. following the presentation of positive clinical data for varegacestat at ESMO. The firm highlighted that varegacestat significantly reduced pain and improved symptoms in desmoid tumor patients across two patient-reported outcome surveys. Despite the stock's high volatility, InvestingPro analysis suggests it is undervalued with a fair value of $20.26, and the company maintains a strong balance sheet.
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Immunome, Inc. presented additional clinical data for its investigational drug, varegacestat, at the 2026 ESMO Congress, highlighting improvements in patient-reported symptom burden and physical function in desmoid tumor patients. These presentations build on previously reported Phase 3 RINGSIDE trial results, which met primary and key secondary endpoints, demonstrating significant improvements in objective response rate, progression-free survival, tumor volume reduction, and pain intensity. The company's NDA for varegacestat has been accepted by the FDA with a PDUFA target action date of April 28, 2027.
Immunome, Inc. Estimates – NASDAQ:IMNM
This article provides an overview of Immunome, Inc. (NASDAQ:IMNM) financial estimates available on TradingView. It highlights where users can find reported financial data and analyst estimates for the income statement, balance sheet, cash flow, and valuation metrics, allowing for comparison of actual results with average, high, and low estimates and visualization of trends over time.
Immunome Stock Gets A Boost In Visibility After William Blair Starts Outperform Coverage
William Blair has initiated coverage of Immunome (NASDAQCM:IMNM) with an Outperform rating, highlighting the company's oncology pipeline, which includes varegacestat and various antibody-drug conjugate and radioligand candidates. This new coverage draws increased attention to Immunome's strategy to transform its pre-revenue portfolio into a diverse oncology platform, primarily targeting desmoid tumors and solid tumor ADC programs. The report emphasizes the potential for a near-term commercial launch of varegacestat, pending regulatory approval.
William Blair Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $35
William Blair has initiated coverage of Immunome (IMNM.US) with a Buy rating. The firm has also set a target price of $35 for the company's stock.
William Blair initiates Immunome stock coverage with outperform rating
William Blair has initiated coverage on Immunome Inc. (NASDAQ:IMNM) with an Outperform rating and a $35 price target, citing the company's lead drug varegacestat for desmoid tumors and its antibody-drug conjugate pipeline. The firm projects varegacestat sales of $1.4 billion by 2032, with approval expected by April 2027. Despite potential risks, analysts maintain a Strong Buy consensus on the stock.
William Blair Initiates Coverage on Immunome With Outperform Rating
William Blair has initiated coverage on Immunome (IMNM) with an Outperform rating. According to analysts, Immunome currently holds an average rating of buy and a mean price target of $35.20.
Immunome clears FDA IND for IM-1340: what it means for Immunome stock
Immunome has received FDA IND clearance for its drug IM-1340, an antibody-drug conjugate for advanced solid tumors, and plans to initiate a Phase 1 study in Q4 2026. This clearance allows the company to proceed with human testing, evaluating safety and preliminary anti-tumor activity. Analysts have reaffirmed "Buy" ratings for Immunome, highlighting its clinical pipeline and upcoming milestones in regulatory progress and trial execution.
Immunome's Varegacestat: Could It Become The Second FDA-Approved Desmoid Tumor Treatment?
Immunome's investigational drug Varegacestat is being explored as a potential treatment for desmoid tumors, a rare soft-tissue condition. Currently, the only FDA-approved treatment for desmoid tumors is Ogsiveo, developed by SpringWorks Therapeutics and now part of Merck KGaA. The article suggests that Varegacestat could emerge as a competitor to Ogsiveo.
Immunome (IMNM) Stock Dropped, What Is Behind The Latest Attention?
Immunome (IMNM) stock recently dropped 8.2% in one day and 28.7% over 30 days, despite a 24.7% annual return, following FDA clearance for its IM-1340 IND application. The company is now seen as 52% undervalued by many investors, trading at a steep discount to fair value and analyst targets. Immunome is expanding its oncology platform with multiple assets in Phase 1 and more INDs planned, which could support multi-asset revenue streams.
Immunome (IMNM) Stock Dropped, What Is Behind The Latest Attention?
Immunome (IMNM) stock recently dropped by 8.2% in one day and 28.7% over 30 days, despite a 24.7% increase over the last year. This dip follows FDA clearance for its IND application for IM-1340, an antibody-drug conjugate for advanced solid tumors. The company is seen as 52% undervalued by some analysts, with a fair value of $36.31, largely due to its expanding oncology platform and multiple pipeline assets.
Price-Driven Insight from (IMNM) for Rule-Based Strategy
This article provides a price-driven analysis for Immunome Inc. (NASDAQ: IMNM), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details AI-generated trading strategies including Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests elevated downside risk due to the absence of additional long-term support signals.
Does FDA Trial Clearance Change The Bull Case For Immunome (IMNM)?
Immunome (IMNM) received FDA clearance for its IND for IM-1340, an ADC targeting advanced solid tumors, moving it into Phase 1 trials. This development advances Immunome's oncology platform, focusing on unmet needs, but also highlights the company's continued cash burn and financing requirements due to lack of product revenue. The clearance, alongside recent new hires, signals a strategic expansion of Immunome's pipeline and operational capabilities, tying employee incentives to the long-term success of its drug portfolio.
Immunome (IMNM) Wins FDA IND Clearance, Is It Still 47% Below Fair Value?
Immunome (IMNM) has received FDA IND clearance for IM-1340, an antibody-drug conjugate for advanced solid tumors, leading to increased focus on the company's oncology pipeline. Despite recent short-term share price drops, longer-term investors have seen significant gains. The stock is currently considered 47% undervalued by some narratives, trading at $19.31 against a fair value of $36.31, due to expectations for its growing oncology platform.
Immunome (IMNM) Wins FDA IND Clearance, Is It Still 47% Below Fair Value?
Immunome (IMNM) recently received FDA IND clearance for its IM-1340 program, an antibody-drug conjugate for advanced solid tumors. Despite recent share price pullbacks, the company's long-term shareholder returns remain strong. Analysts and a discounted cash flow model suggest Immunome may be undervalued, with fair value estimates significantly above its current trading price, indicating potential opportunities for investors.
Immunome stock holds at Stifel as Bristol deal cleans up license
Stifel has maintained a Hold rating and a $24.00 price target for Immunome Inc. following a licensing agreement with Bristol. Immunome paid $20 million and issued shares to eliminate payment obligations and acquire varegacestat patent rights, simplifying potential ex-US commercialization. Despite the positive move, Stifel believes near-term partnership discussions are unlikely, requiring several quarters of commercial results.
Immunome stock advances clinical pipeline after FDA clearance
Immunome's stock is advancing its clinical pipeline following FDA clearance for IM-1340, an antibody-drug conjugate targeting advanced solid tumors, with a Phase 1 study expected to begin in Q4 2026. Despite a recent quarterly loss and negative cash flow, analyst consensus maintains a "Moderate Buy" rating with a significantly higher average price target than its current trading price. The company's financial health and the success of its clinical trials remain key valuation factors.
Immunome stock holds at Stifel as Bristol deal cleans up license
Stifel maintained a Hold rating on Immunome Inc. with a $24.00 price target after the company's licensing agreement with Bristol, which eliminates future payment obligations and acquires patent rights for varegacestat. This transaction is seen as simplifying potential ex-US commercialization, though Stifel does not anticipate a near-term deal. The company's strong balance sheet and ongoing FDA review for varegacestat were also noted.